Your Article Summary
See Latest ArticlesEffect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study
The Lancet - Early Online Publication, 06/15/09
Henry RR et al. – Short-term clinical data show a favorable safety and efficacy profile for the dual peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonist aleglitazar.
Methods- SYNCHRONY study: double-blind study to establish glucose-lowering and lipid-modifying effects and safety profile of aleglitazar
- Enrollment of type 2 diabetes pts (either drug-naive or pre-treated with ≤2 oral agents) from 47 sites in 7 countries
- Single-blind, placebo run-in period of 4-5 wks
- Randomization of 332 pts double-blind to 16 wk-treatment with aleglitazar at once-daily doses of 50, 150, 300, or 600, or matching placebo (55 pts in each group), or to open-label pioglitazone 45 mg once daily (57 pts) as a reference
- Primary efficacy endpoint: change in glycosylated hemoglobin (HbA1c) concentration from baseline to treatment end
- Efficacy analysis of pts who received ≥1 dose of study drug and had ≥1 evaluable post-baseline HbA1c measurement
- Aleglitazar significantly reduced baseline HbA1c vs placebo in a dose-dependent manner
- Trend of changes over time suggests that maximum effect of aleglitazar on HbA1c concentration not yet reached after 16 wks of treatment
- Edema, hemodilution, and weight gain occurred in a dose-dependent manner
- At aleglitazar doses <300 microg, no pts had congestive heart failure, similar frequency to placebo for edema and less than with pioglitazone, and bodyweight gain was less than with pioglitazone
Related Articles
Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Journal of General Internal Medicine, 11/09/09
Relevance Score: 96%
Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 10/19/09
Relevance Score: 95%
Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study
Clinical Endocrinology, 10/16/09
Relevance Score: 94%
Periodontal Disease – The Overlooked Diabetes Complication
Nephrology Nursing Journal, 10/07/09
Relevance Score: 94%
Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type 1 diabetes
Diabetic Medicine, 10/05/09
Relevance Score: 94%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Growth Hormone (GH) Deficiency Type II: A Novel GH-1 Gene Mutation (GH-R178H) Affecting Secretion and Action
Journal of Clinical Endocrinology and Metabolism, 12/11/09
Anti Insulin-Like Growth Factor I Receptor Immunoliposomes: A Single Formulation Combining Two Anticancer Treatments with Enhanced Therapeutic Efficiency
Journal of Clinical Endocrinology and Metabolism, 12/11/09
Ghrelin and polypeptide YY in postpartum lactating and nonlactating women
American Journal of Clinical Nutrition, 12/11/09
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09
Are short women at risk for gestational diabetes mellitus
European Journal of Endocrinology, 12/11/09
Nicotinamide overload may play a role in the development of type 2 diabetes
World Journal of Gastroenterology, 12/11/09